Status:

COMPLETED

Study of Phosphorylated Metabolism Profile as Predictive Biomarker of Cognitive Decline in Memory Complaint.

Lead Sponsor:

Poitiers University Hospital

Conditions:

Memory Complaint

Alzheimer Disease

Eligibility:

All Genders

Up to 90 years

Phase:

NA

Brief Summary

Alzheimer disease is a frequent disease in the late ages that results in global alteration of cognitive functions. In which memory complaint can be isolated in the early stages. Physiopathology of ne...

Eligibility Criteria

Inclusion

  • Memory complaint, leading to a medical visit at the Centre Mémoire de Ressources et de Recherche (CMRR) of Poitiers, and for which an MRI is needed in routine exploration.
  • Age inferior at 90 years old
  • Mini Mental State Examination (MMSE) score between 20 and 30
  • Patient without guardianship measure, without restricted liberty.
  • Patient who benefits from social security

Exclusion

  • Vascular, tumor, inflammatory pathology diagnosed by MRI
  • Other diagnosed neurodegenerative disease than Alzheimer disease
  • Other non neurodegenerative neurological disease
  • Vital risk at short term
  • Severe and uncontrolled psychiatric disease

Key Trial Info

Start Date :

April 8 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 15 2023

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT03863041

Start Date

April 8 2019

End Date

June 15 2023

Last Update

October 6 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHU of Poitiers

Poitiers, France

Study of Phosphorylated Metabolism Profile as Predictive Biomarker of Cognitive Decline in Memory Complaint. | DecenTrialz